Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
DMAC DiaMedica Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: DMAC
Price (delayed)
$4.2
Market cap
$180.11M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.64
Enterprise value
$177.64M
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments to improve the lives of patients with neurological and chronic kidney diseases.
Highlights
DMAC's debt is down by 17% year-on-year and by 7% since the previous quarter
The quick ratio has plunged by 56% YoY and by 4.3% from the previous quarter
The net income has contracted by 39% YoY and by 10% from the previous quarter
Key stats
What are the main financial stats of DMAC
Market
Valuations
Earnings
Shares outstanding
42.88M
Market cap
$180.11M
Enterprise value
$177.64M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.3
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$28.64M
Net income
-$26.97M
EBIT
-$26.94M
EBITDA
-$26.83M
Free cash flow
-$22.6M
Per share
Balance sheet
Liquidity
EPS
-$0.64
EPS diluted
-$0.64
Free cash flow per share
-$0.53
Book value per share
$0.79
Revenue per share
$0
TBVPS
$0.91
Total assets
$38.83M
Total liabilities
$4.88M
Debt
$316,000
Equity
$33.95M
Working capital
$32.76M
Debt to equity
0.01
Current ratio
8.02
Quick ratio
7.88
Net debt/EBITDA
0.09
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-55.5%
Return on equity
-61.3%
Return on invested capital
-69.8%
Return on capital employed
-78.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DMAC stock price
How has the DiaMedica Therapeutics stock price performed over time
Intraday
1.94%
1 week
0.96%
1 month
-0.71%
1 year
48.94%
YTD
-22.65%
QTD
10.82%
Financial performance
How have DiaMedica Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$28.64M
Net income
-$26.97M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 39% YoY and by 10% from the previous quarter
The operating income has contracted by 37% YoY and by 7% from the previous quarter
Price vs fundamentals
How does DMAC's price correlate with its fundamentals
Growth
What is DiaMedica Therapeutics's growth rate over time
Valuation
What is DiaMedica Therapeutics stock price valuation
P/E
N/A
P/B
5.3
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 14% YoY and by 7% QoQ
The stock's price to book (P/B) is 61% more than its 5-year quarterly average of 3.3 and 29% more than its last 4 quarters average of 4.1
DiaMedica Therapeutics's equity has decreased by 27% YoY and by 17% from the previous quarter
Efficiency
How efficient is DiaMedica Therapeutics business performance
DiaMedica Therapeutics's return on invested capital has shrunk by 82% YoY and by 20% QoQ
DiaMedica Therapeutics's return on equity has shrunk by 68% YoY and by 18% QoQ
The return on assets has dropped by 60% year-on-year and by 16% since the previous quarter
Dividends
What is DMAC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DMAC.
Financial health
How did DiaMedica Therapeutics financials performed over time
DiaMedica Therapeutics's total liabilities has soared by 68% YoY but it has decreased by 13% from the previous quarter
The current ratio has shrunk by 56% YoY and by 3.1% QoQ
DMAC's debt is 99% smaller than its equity
DiaMedica Therapeutics's equity has decreased by 27% YoY and by 17% from the previous quarter
DMAC's debt is down by 17% year-on-year and by 7% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.